Trial
NCT02875002
Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Yale University
Collaborators
Massey Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Condition
Relapsed and Refractory Aggressive B- and T-cell Lymphomas
Intervention
volasertib
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-22